Brett King

11.3k total citations · 6 hit papers
175 papers, 6.5k citations indexed

About

Brett King is a scholar working on Urology, Dermatology and Pathology and Forensic Medicine. According to data from OpenAlex, Brett King has authored 175 papers receiving a total of 6.5k indexed citations (citations by other indexed papers that have themselves been cited), including 78 papers in Urology, 56 papers in Dermatology and 49 papers in Pathology and Forensic Medicine. Recurrent topics in Brett King's work include Hair Growth and Disorders (78 papers), Autoimmune Bullous Skin Diseases (43 papers) and Dermatology and Skin Diseases (21 papers). Brett King is often cited by papers focused on Hair Growth and Disorders (78 papers), Autoimmune Bullous Skin Diseases (43 papers) and Dermatology and Skin Diseases (21 papers). Brett King collaborates with scholars based in United States, Australia and Japan. Brett King's co-authors include Brittany G. Craiglow, William Damsky, Lucy Liu, Shanta R. Dube, Karena H. Nguyen, Rutul Patel, Steven G. Boxer, Gabbi Promoff, Sameer Alam and René A. Arrazola and has published in prestigious journals such as New England Journal of Medicine, Proceedings of the National Academy of Sciences and The Lancet.

In The Last Decade

Brett King

165 papers receiving 6.3k citations

Hit Papers

Trends in Awareness and U... 2014 2026 2018 2022 2014 2017 2016 2021 2023 100 200 300 400
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Trends in Awareness and Use of Electronic Cigarettes Among US Adults, 2010-2013
    2014 441 citations Brett King et al. profile →
  2. JAK inhibitors in dermatology: The promise of a new drug class
    2017 357 citations William Damsky, Brett King Journal of the American Academy of Dermatology profile →
  3. Tofacitinib for the treatment of severe alopecia areata and variants: A study of 90 patients
    2016 241 citations Brett King et al. Journal of the American Academy of Dermatology profile →
  4. A phase 2a randomized, placebo-controlled study to evaluate the efficacy and safety of the oral Janus kinase inhibitors ritlecitinib and brepocitinib in alopecia areata: 24-week results
    2021 138 citations Brett King, Emma Guttman‐Yassky et al. Journal of the American Academy of Dermatology profile →
  5. Efficacy and safety of ritlecitinib in adults and adolescents with alopecia areata: a randomised, double-blind, multicentre, phase 2b–3 trial
    2023 134 citations Brett King, Natasha Atanaskova Mesinkovska et al. profile →
  6. Efficacy and Safety of Baricitinib in Patients with Severe Alopecia Areata over 52 Weeks of Continuous Therapy in Two Phase III Trials (BRAVE-AA1 and BRAVE-AA2)
    2023 65 citations Ohsang Kwon, Maryanne M. Senna et al. American Journal of Clinical Dermatology profile →

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author Last Decade Papers Cites
Brett King 2.2k 1.9k 1.6k 1.2k 982 175 6.5k
Miguel Quintanilla 368 0.2× 137 0.1× 289 0.2× 727 0.6× 163 0.2× 134 7.7k
Margaret A. Knowles 122 0.1× 438 0.2× 287 0.2× 1.0k 0.8× 253 0.3× 229 13.6k
Michael Sorkin 349 0.2× 206 0.1× 296 0.2× 81 0.1× 212 0.2× 124 5.4k
Andrew F. Walls 681 0.3× 40 0.0× 3.9k 2.5× 330 0.3× 1.2k 1.2× 252 10.1k
John Ryan 202 0.1× 72 0.0× 1.2k 0.8× 280 0.2× 453 0.5× 208 9.6k
Simon P. Robins 127 0.1× 127 0.1× 599 0.4× 922 0.8× 1.2k 1.3× 159 8.2k
Haralabos P. Kalofonos 897 0.4× 45 0.0× 516 0.3× 740 0.6× 95 0.1× 384 10.3k
Ronald Hoffman 90 0.0× 161 0.1× 547 0.3× 288 0.2× 2.1k 2.1× 364 12.2k
D. Neil Watkins 140 0.1× 151 0.1× 485 0.3× 1.1k 0.9× 126 0.1× 161 12.1k
Hua He 245 0.1× 72 0.0× 473 0.3× 75 0.1× 556 0.6× 176 5.7k

Countries citing papers authored by Brett King

Since Specialization
Citations

This map shows the geographic impact of Brett King's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Brett King with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Brett King more than expected).

Fields of papers citing papers by Brett King

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Brett King. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Brett King. The network helps show where Brett King may publish in the future.

Co-authorship network of co-authors of Brett King

This figure shows the co-authorship network connecting the top 25 collaborators of Brett King. A scholar is included among the top collaborators of Brett King based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Brett King. Brett King is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
King, Brett, et al.. (2025). Efficacy and safety of etrasimod in alopecia areata: A multicentre, randomized, double‐blind, placebo‐controlled, Phase 2 study. Journal of the European Academy of Dermatology and Venereology. 39(6). 1174–1184. 1 indexed citations
2.
3.
King, Brett, Jennifer Soung, Christos Tziotzios, et al.. (2024). Integrated Safety Analysis of Ritlecitinib, an Oral JAK3/TEC Family Kinase Inhibitor, for the Treatment of Alopecia Areata from the ALLEGRO Clinical Trial Program. American Journal of Clinical Dermatology. 25(2). 299–314. 27 indexed citations
4.
Mesinkovska, Natasha Atanaskova, Brett King, Sergio Vañó‐Galván, et al.. (2024). Visualizing Severity of Alopecia Tool (SALT) scores in the clinical setting using patient images from a clinical trial. SHILAP Revista de lepidopterología. 3(2). 528–535. 3 indexed citations
5.
Senna, Maryanne M., Arash Mostaghimi, Manabu Ohyama, et al.. (2024). Long‐term efficacy and safety of baricitinib in patients with severe alopecia areata: 104‐week results from BRAVE‐AA1 and BRAVE‐AA2. Journal of the European Academy of Dermatology and Venereology. 38(3). 583–593. 21 indexed citations
6.
Passeron, Thierry, Brett King, Julien Sénéschal, et al.. (2023). Inhibition of T-cell activity in alopecia areata: recent developments and new directions. Frontiers in Immunology. 14. 1243556–1243556. 40 indexed citations
7.
8.
Soung, Jennifer, Brett King, Christos Tziotzios, et al.. (2023). 43117 Integrated safety analysis of ritlecitinib in adolescent patients with alopecia areata from the randomized, placebo-controlled ALLEGRO phase 2b/3 and ongoing open-label phase 3 ALLEGRO-LT studies. Journal of the American Academy of Dermatology. 89(3). AB182–AB182. 1 indexed citations
9.
Kwon, Ohsang, Maryanne M. Senna, Rodney Sinclair, et al.. (2023). Efficacy and Safety of Baricitinib in Patients with Severe Alopecia Areata over 52 Weeks of Continuous Therapy in Two Phase III Trials (BRAVE-AA1 and BRAVE-AA2). American Journal of Clinical Dermatology. 24(3). 443–451. 65 indexed citations breakdown →
10.
Senna, Maryanne M., Ohsang Kwon, Bianca Maria Piraccini, et al.. (2023). Clinical Benefits of Baricitinib Therapy According to Scalp Hair Regrowth in Patients with Severe Alopecia Areata. Dermatology and Therapy. 13(12). 3209–3220. 2 indexed citations
11.
King, Brett, Arash Mostaghimi, Yutaka Shimomura, et al.. (2022). Integrated safety analysis of baricitinib in adults with severe alopecia areata from two randomized clinical trials. British Journal of Dermatology. 188(2). 218–227. 37 indexed citations
12.
King, Brett, Emma Guttman‐Yassky, Elena Peeva, et al.. (2022). Safety and Efficacy of Ritlecitinib and Brepocitinib in Alopecia Areata: Results from the Crossover Open-Label Extension of the ALLEGRO Phase 2a Trial. SHILAP Revista de lepidopterología. 2(6). 100156–100156. 15 indexed citations
13.
Wyrwich, Kathleen W., Helen Kitchen, S.L. Knight, et al.. (2022). Using qualitative methods to establish the clinically meaningful threshold for treatment success in alopecia areata. Quality of Life Research. 32(5). 1319–1327. 4 indexed citations
14.
Damsky, William, Alice Wang, Daniel Kim, et al.. (2022). Inhibition of type 1 immunity with tofacitinib is associated with marked improvement in longstanding sarcoidosis. Nature Communications. 13(1). 3140–3140. 62 indexed citations
15.
Wang, Alice, Alexander L. Fogel, Michael J. Murphy, et al.. (2021). Cytokine RNA In Situ Hybridization Permits Individualized Molecular Phenotyping in Biopsies of Psoriasis and Atopic Dermatitis. SHILAP Revista de lepidopterología. 1(2). 100021–100021. 26 indexed citations
16.
Guttman‐Yassky, Emma, Ana B. Pavel, Aisleen Diaz, et al.. (2021). Ritlecitinib and brepocitinib demonstrate significant improvement in scalp alopecia areata biomarkers. Journal of Allergy and Clinical Immunology. 149(4). 1318–1328. 74 indexed citations
17.
Wyrwich, Kathleen W., Helen Kitchen, S.L. Knight, et al.. (2020). The Alopecia Areata Investigator Global Assessment scale: a measure for evaluating clinically meaningful success in clinical trials. British Journal of Dermatology. 183(4). 702–709. 67 indexed citations
18.
Wyrwich, Kathleen W., Helen Kitchen, S.L. Knight, et al.. (2020). The Role of Patients in Alopecia Areata Endpoint Development: Understanding Physical Signs and Symptoms. Journal of Investigative Dermatology Symposium Proceedings. 20(1). S71–S77. 5 indexed citations
19.
Wyrwich, Kathleen W., Helen Kitchen, S.L. Knight, et al.. (2020). Development of Clinician-Reported Outcome (ClinRO) and Patient-Reported Outcome (PRO) Measures for Eyebrow, Eyelash and Nail Assessment in Alopecia Areata. American Journal of Clinical Dermatology. 21(5). 725–732. 41 indexed citations
20.
Wyrwich, Kathleen W., Helen Kitchen, S.L. Knight, et al.. (2020). Development of the Scalp Hair Assessment PRO™ measure for alopecia areata. British Journal of Dermatology. 183(6). 1065–1072. 27 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Miguel Quintanilla Breakdown of academic impact, for papers by Margaret A. Knowles Breakdown of academic impact, for papers by Michael Sorkin Breakdown of academic impact, for papers by Andrew F. Walls Breakdown of academic impact, for papers by John Ryan Breakdown of academic impact, for papers by Simon P. Robins Breakdown of academic impact, for papers by Haralabos P. Kalofonos Breakdown of academic impact, for papers by Ronald Hoffman Breakdown of academic impact, for papers by D. Neil Watkins Breakdown of academic impact, for papers by Hua He
Rankless by CCL
2026